• Targeting BCL-XL and MCL-1 in Glioblastoma: New Apoptosis In

  2026-07-29

  This study reveals that glioblastoma (GBM) cells exhibit increased expression of anti-apoptotic BCL-xL and MCL-1, making them highly susceptible to apoptosis induction by BH3-mimetics. Sequential inhibition of these proteins produces robust anti-tumor effects in preclinical GBM models, offering a promising strategy against drug-resistant brain tumors.

• Toremifene Citrate: Mechanistic Insight and Translational St

  2026-07-29

  Explore how Toremifene Citrate—a potent oral selective estrogen receptor modulator—drives innovation in breast cancer and endocrinology research. This article delivers a mechanistic deep dive, comparative evidence, strategic protocol recommendations, and actionable guidance for translational scientists seeking to optimize estrogen receptor signaling studies and bridge bench-to-bedside impact.

• Dual Glutamate Receptor Blockade Mitigates Soman-Induced Neu

  2026-07-28

  The reference study demonstrates that dual antagonism of AMPA and NMDA receptors with IEM-1925 confers potent antiseizure, neuroprotective, and cognitive benefits in a rat model of soman-induced status epilepticus. These findings highlight a mechanistically targeted approach to counteract organophosphorus nerve agent (OPNA) toxicity and inform future strategies for neuroprotection.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Precision for pH &

  2026-07-28

  5-(N,N-dimethyl)-Amiloride hydrochloride from APExBIO stands out for its selective, potent NHE inhibition—enabling reproducible control of intracellular pH and robust modeling of endothelial injury and cardiac dysfunction. This article presents evidence-backed workflow enhancements, troubleshooting advice, and practical insights to optimize research on ion transport and sepsis-linked vascular damage.

• Meropenem Trihydrate: Strategic Leverage in Resistance Resea

  2026-07-27

  Explore how Meropenem trihydrate, a broad-spectrum carbapenem antibiotic, is redefining the landscape of translational infectious disease research. We connect mechanistic insights—drawn from cutting-edge metabolomics of carbapenemase resistance—to strategic guidance for designing robust translational studies, highlighting competitive positioning and clinical relevance. Protocol parameters and outlook are tailored for scientific teams seeking both experimental rigor and future-proofed methodologies.

• A 83-01 in Organoid-Based TGF-β Pathway Research: Beyond EMT

  2026-07-27

  Explore how A 83-01, a potent ALK-5 inhibitor, is revolutionizing advanced TGF-β signaling pathway studies using organoid models. Uncover unique insights on optimizing assay design, selectivity, and translational relevance for cancer and fibrosis research.

• Fludarabine: DNA Synthesis Inhibitor for Oncology Research

  2026-07-26

  Fludarabine stands out as an essential DNA synthesis inhibitor for leukemia and multiple myeloma research, enabling robust apoptosis modeling and precision genomic studies. This article provides a detailed protocol, actionable troubleshooting, and advanced applications to help researchers optimize Fludarabine-based workflows.

• (S)-(+)-Methoprene: Selective Juvenile Hormone Analog for Re

  2026-07-25

  (S)-(+)-Methoprene is a highly selective juvenile hormone analog that potently inhibits insect metamorphosis by activating the Methoprene-tolerant (Met) receptor. It is widely used as a benchmark compound in arthropod developmental biology and endocrine disruption studies. Its low mammalian toxicity makes it a valuable tool for comparative receptor research and insecticide mode-of-action assays.

• Meropenem Workflows: Applied β-Lactam Carbapenem Research

  2026-07-24

  Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, is pivotal for modeling and dissecting resistance in Gram-negative and Gram-positive pathogens. This guide distills advanced experimental workflows, troubleshooting tips, and novel resistance insights—enabling translational researchers to optimize antibacterial agent deployment in the lab.

• Immune-Adapted Bacterial Evasion Reveals Host Defense Target

  2026-07-24

  Russell et al. leverage immune-adaptive pathogen variation to uncover key macrophage mediators involved in gram-positive bacterial killing, including NAMPT and P2RX7. Their approach demonstrates how pathogen-driven host response screening identifies actionable targets for host-directed therapies against antimicrobial-resistant infections.

• Mitoxantrone Targets ERα DBD-LBD Interface for Degradation

  2026-07-23

  Wang et al. reveal that Mitoxantrone, a DNA topoisomerase II inhibitor, disrupts estrogen receptor alpha (ERα) by binding its DBD-LBD interface, leading to proteasomal degradation—even in therapy-resistant mutants. This study establishes a novel allosteric site for overcoming endocrine resistance and expands the mechanistic repertoire for selective nuclear receptor modulation.

• LSKL Attenuates DHEA-Induced Oxidative Stress in Rat Granulo

  2026-07-23

  The referenced study demonstrates that the peptide LSKL can mitigate dehydroepiandrosterone (DHEA)-induced apoptosis and oxidative stress in rat granulosa cells by targeting the THBS1/PI3K/AKT pathway. These findings identify thrombospondin-1 as a promising therapeutic target in polycystic ovary syndrome (PCOS) and highlight LSKL’s potential to restore ovarian function.

• AMG 9810: Optimizing TRPV1 Antagonist Workflows in Pain Rese

  2026-07-22

  AMG 9810 stands out as a nanomolar-potency TRPV1 antagonist ideal for dissecting pain and metabolic stress mechanisms. This guide delivers stepwise protocols, troubleshooting, and experimental insights to maximize data quality in sensory neuron signaling and metabolic adaptation research.

• AMPK–JAK2/STAT3 Axis Modulates Macrophage Polarization in Ob

  2026-07-22

  This study demonstrates that AMPK activation attenuates airway inflammation in obesity-related asthma by inhibiting M1 macrophage polarization via the JAK2/STAT3 pathway. The work identifies a mechanistic link between metabolic regulation and immune responses, offering new targets for asthma interventions resistant to conventional therapies.

• Deferasirox: Oral Iron Chelator for Cancer Research Workflow

  2026-07-21

  Deferasirox is redefining translational oncology by integrating iron chelation with cutting-edge ferroptosis research. This guide details proven experimental workflows, troubleshooting strategies, and new mechanistic insights—empowering scientists to leverage Deferasirox for both iron overload and cancer cell death modulation.

13609 records 1/908 page Next 12345 下5页 Last page